Ilaris, which is currently approved for orphan indications and sells about $250 per annum, will likely become one of the pharma industry’s biggest-selling drugs as a consequence of these new data. Dosing in the CANTOS study was once every three months.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.